nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadodiamide—Chills—Fludarabine—lymphatic system cancer	0.00509	0.00509	CcSEcCtD
Gadodiamide—Arrhythmia—Fludarabine—lymphatic system cancer	0.00506	0.00506	CcSEcCtD
Gadodiamide—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00504	0.00504	CcSEcCtD
Gadodiamide—Hyponatraemia—Vincristine—lymphatic system cancer	0.00503	0.00503	CcSEcCtD
Gadodiamide—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.005	0.005	CcSEcCtD
Gadodiamide—Ataxia—Carmustine—lymphatic system cancer	0.00493	0.00493	CcSEcCtD
Gadodiamide—Hyponatraemia—Mitoxantrone—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Gadodiamide—Chest pain—Teniposide—lymphatic system cancer	0.00478	0.00478	CcSEcCtD
Gadodiamide—Lung disorder—Methotrexate—lymphatic system cancer	0.00473	0.00473	CcSEcCtD
Gadodiamide—Ataxia—Vincristine—lymphatic system cancer	0.00471	0.00471	CcSEcCtD
Gadodiamide—Oedema—Teniposide—lymphatic system cancer	0.00458	0.00458	CcSEcCtD
Gadodiamide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00458	0.00458	CcSEcCtD
Gadodiamide—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00458	0.00458	CcSEcCtD
Gadodiamide—Blood creatinine increased—Mitoxantrone—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Gadodiamide—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Gadodiamide—Infection—Teniposide—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Gadodiamide—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00454	0.00454	CcSEcCtD
Gadodiamide—Tachycardia—Teniposide—lymphatic system cancer	0.00447	0.00447	CcSEcCtD
Gadodiamide—Malaise—Fludarabine—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Gadodiamide—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00443	0.00443	CcSEcCtD
Gadodiamide—Pruritus—Mechlorethamine—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Gadodiamide—Hypotension—Teniposide—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Gadodiamide—Convulsion—Fludarabine—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Gadodiamide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00425	0.00425	CcSEcCtD
Gadodiamide—Arthralgia—Fludarabine—lymphatic system cancer	0.0042	0.0042	CcSEcCtD
Gadodiamide—Myalgia—Fludarabine—lymphatic system cancer	0.0042	0.0042	CcSEcCtD
Gadodiamide—Discomfort—Fludarabine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Gadodiamide—Sweating increased—Mitoxantrone—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Gadodiamide—Dyspnoea—Teniposide—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Gadodiamide—Oedema—Fludarabine—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Gadodiamide—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Gadodiamide—Infection—Fludarabine—lymphatic system cancer	0.004	0.004	CcSEcCtD
Gadodiamide—Renal failure—Carmustine—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Gadodiamide—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Gadodiamide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Gadodiamide—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Gadodiamide—Rash—Mechlorethamine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Gadodiamide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Gadodiamide—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Gadodiamide—Flushing—Bleomycin—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Gadodiamide—Extravasation—Methotrexate—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Gadodiamide—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Gadodiamide—Myocardial infarction—Vincristine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Gadodiamide—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Gadodiamide—Feeling abnormal—Teniposide—lymphatic system cancer	0.00378	0.00378	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00375	0.00375	CcSEcCtD
Gadodiamide—Chills—Bleomycin—lymphatic system cancer	0.00373	0.00373	CcSEcCtD
Gadodiamide—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Gadodiamide—Renal failure—Mitoxantrone—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Gadodiamide—Nausea—Mechlorethamine—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Gadodiamide—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Gadodiamide—Urticaria—Teniposide—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Gadodiamide—Abdominal pain—Teniposide—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Gadodiamide—Body temperature increased—Teniposide—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Gadodiamide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00362	0.00362	CcSEcCtD
Gadodiamide—Hallucination—Carmustine—lymphatic system cancer	0.00361	0.00361	CcSEcCtD
Gadodiamide—Dyspnoea—Fludarabine—lymphatic system cancer	0.00359	0.00359	CcSEcCtD
Gadodiamide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Gadodiamide—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Gadodiamide—Visual impairment—Carmustine—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Gadodiamide—Fatigue—Fludarabine—lymphatic system cancer	0.00347	0.00347	CcSEcCtD
Gadodiamide—Hallucination—Vincristine—lymphatic system cancer	0.00345	0.00345	CcSEcCtD
Gadodiamide—Pain—Fludarabine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Gadodiamide—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00342	0.00342	CcSEcCtD
Gadodiamide—Urethral disorder—Vincristine—lymphatic system cancer	0.00339	0.00339	CcSEcCtD
Gadodiamide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Gadodiamide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Gadodiamide—Flushing—Carmustine—lymphatic system cancer	0.00337	0.00337	CcSEcCtD
Gadodiamide—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Gadodiamide—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Gadodiamide—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Gadodiamide—Asthenia—Teniposide—lymphatic system cancer	0.00329	0.00329	CcSEcCtD
Gadodiamide—Melaena—Methotrexate—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Gadodiamide—Malaise—Bleomycin—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Gadodiamide—Pruritus—Teniposide—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Gadodiamide—Arrhythmia—Carmustine—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Gadodiamide—Body temperature increased—Fludarabine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Gadodiamide—Diarrhoea—Teniposide—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Gadodiamide—Chest pain—Bleomycin—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Gadodiamide—Myalgia—Bleomycin—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Gadodiamide—Coma—Methotrexate—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Gadodiamide—Discomfort—Bleomycin—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Gadodiamide—Chills—Mitoxantrone—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Gadodiamide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00301	0.00301	CcSEcCtD
Gadodiamide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Gadodiamide—Tremor—Carmustine—lymphatic system cancer	0.00296	0.00296	CcSEcCtD
Gadodiamide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Gadodiamide—Oedema—Bleomycin—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Gadodiamide—Infection—Bleomycin—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Gadodiamide—Vomiting—Teniposide—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Gadodiamide—Asthenia—Fludarabine—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Gadodiamide—Rash—Teniposide—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Gadodiamide—Dermatitis—Teniposide—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Gadodiamide—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Gadodiamide—Headache—Teniposide—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Gadodiamide—Pruritus—Fludarabine—lymphatic system cancer	0.00285	0.00285	CcSEcCtD
Gadodiamide—Hypotension—Bleomycin—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Gadodiamide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00276	0.00276	CcSEcCtD
Gadodiamide—Convulsion—Carmustine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Gadodiamide—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Gadodiamide—Nausea—Teniposide—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Gadodiamide—Chest pain—Carmustine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Gadodiamide—Myalgia—Carmustine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Gadodiamide—Anxiety—Carmustine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Gadodiamide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Gadodiamide—Malaise—Mitoxantrone—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Gadodiamide—Dyspnoea—Bleomycin—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Gadodiamide—Renal failure acute—Methotrexate—lymphatic system cancer	0.00263	0.00263	CcSEcCtD
Gadodiamide—Convulsion—Vincristine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Gadodiamide—Oedema—Carmustine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Gadodiamide—Myalgia—Vincristine—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Gadodiamide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Gadodiamide—Infection—Carmustine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Gadodiamide—Vomiting—Fludarabine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Gadodiamide—Convulsion—Mitoxantrone—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Gadodiamide—Rash—Fludarabine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Gadodiamide—Dermatitis—Fludarabine—lymphatic system cancer	0.00254	0.00254	CcSEcCtD
Gadodiamide—Pain—Bleomycin—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Gadodiamide—Headache—Fludarabine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Gadodiamide—Tachycardia—Carmustine—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Gadodiamide—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Gadodiamide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Gadodiamide—Chest pain—Mitoxantrone—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Gadodiamide—Myalgia—Mitoxantrone—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Gadodiamide—Anxiety—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Gadodiamide—Discomfort—Mitoxantrone—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Gadodiamide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Gadodiamide—Oedema—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Gadodiamide—Infection—Vincristine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Gadodiamide—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Gadodiamide—Nervous system disorder—Vincristine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Gadodiamide—Hypotension—Carmustine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Gadodiamide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Gadodiamide—Oedema—Mitoxantrone—lymphatic system cancer	0.0024	0.0024	CcSEcCtD
Gadodiamide—Nausea—Fludarabine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Gadodiamide—Infection—Mitoxantrone—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Gadodiamide—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Gadodiamide—Shock—Mitoxantrone—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Gadodiamide—Urticaria—Bleomycin—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Gadodiamide—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00234	0.00234	CcSEcCtD
Gadodiamide—Body temperature increased—Bleomycin—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Gadodiamide—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Gadodiamide—Paraesthesia—Carmustine—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Gadodiamide—Hypotension—Vincristine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Gadodiamide—Dyspnoea—Carmustine—lymphatic system cancer	0.0023	0.0023	CcSEcCtD
Gadodiamide—Somnolence—Carmustine—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Gadodiamide—Ataxia—Methotrexate—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Gadodiamide—Hypotension—Mitoxantrone—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Gadodiamide—Paraesthesia—Vincristine—lymphatic system cancer	0.00221	0.00221	CcSEcCtD
Gadodiamide—Pain—Carmustine—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Gadodiamide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00218	0.00218	CcSEcCtD
Gadodiamide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Gadodiamide—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Gadodiamide—Somnolence—Mitoxantrone—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Gadodiamide—Feeling abnormal—Carmustine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Gadodiamide—Fatigue—Vincristine—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Gadodiamide—Asthenia—Bleomycin—lymphatic system cancer	0.00212	0.00212	CcSEcCtD
Gadodiamide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00211	0.00211	CcSEcCtD
Gadodiamide—Pain—Vincristine—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Gadodiamide—Pruritus—Bleomycin—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Gadodiamide—Fatigue—Mitoxantrone—lymphatic system cancer	0.00207	0.00207	CcSEcCtD
Gadodiamide—Pain—Mitoxantrone—lymphatic system cancer	0.00205	0.00205	CcSEcCtD
Gadodiamide—Body temperature increased—Carmustine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Gadodiamide—Abdominal pain—Carmustine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Gadodiamide—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00196	0.00196	CcSEcCtD
Gadodiamide—Abdominal pain—Vincristine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Gadodiamide—Body temperature increased—Vincristine—lymphatic system cancer	0.00194	0.00194	CcSEcCtD
Gadodiamide—Urticaria—Mitoxantrone—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Gadodiamide—Hypersensitivity—Carmustine—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Gadodiamide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Gadodiamide—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Gadodiamide—Vomiting—Bleomycin—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Gadodiamide—Rash—Bleomycin—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Gadodiamide—Dermatitis—Bleomycin—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Gadodiamide—Asthenia—Carmustine—lymphatic system cancer	0.00185	0.00185	CcSEcCtD
Gadodiamide—Renal failure—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Gadodiamide—Hypersensitivity—Vincristine—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Gadodiamide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Gadodiamide—Asthenia—Vincristine—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Gadodiamide—Diarrhoea—Carmustine—lymphatic system cancer	0.00176	0.00176	CcSEcCtD
Gadodiamide—Nausea—Bleomycin—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Gadodiamide—Asthenia—Mitoxantrone—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Gadodiamide—Dizziness—Carmustine—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Gadodiamide—Diarrhoea—Vincristine—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Gadodiamide—Pharyngitis—Methotrexate—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Gadodiamide—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Gadodiamide—Urethral disorder—Methotrexate—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Gadodiamide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Gadodiamide—Vomiting—Carmustine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Gadodiamide—Dizziness—Vincristine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gadodiamide—Rash—Carmustine—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Gadodiamide—Dermatitis—Carmustine—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Gadodiamide—Visual impairment—Methotrexate—lymphatic system cancer	0.00162	0.00162	CcSEcCtD
Gadodiamide—Headache—Carmustine—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Gadodiamide—Tinnitus—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Gadodiamide—Vomiting—Vincristine—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Gadodiamide—Rash—Vincristine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Gadodiamide—Dermatitis—Vincristine—lymphatic system cancer	0.00155	0.00155	CcSEcCtD
Gadodiamide—Headache—Vincristine—lymphatic system cancer	0.00154	0.00154	CcSEcCtD
Gadodiamide—Nausea—Carmustine—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Gadodiamide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Gadodiamide—Rash—Mitoxantrone—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Gadodiamide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Gadodiamide—Chills—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Gadodiamide—Headache—Mitoxantrone—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Gadodiamide—Nausea—Vincristine—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Gadodiamide—Dysgeusia—Methotrexate—lymphatic system cancer	0.00143	0.00143	CcSEcCtD
Gadodiamide—Nausea—Mitoxantrone—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Gadodiamide—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Gadodiamide—Malaise—Methotrexate—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Gadodiamide—Convulsion—Methotrexate—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Gadodiamide—Arthralgia—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Gadodiamide—Chest pain—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Gadodiamide—Myalgia—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Gadodiamide—Discomfort—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Gadodiamide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Gadodiamide—Infection—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Gadodiamide—Nervous system disorder—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Gadodiamide—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Gadodiamide—Hypotension—Methotrexate—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Gadodiamide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Gadodiamide—Paraesthesia—Methotrexate—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Gadodiamide—Dyspnoea—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Gadodiamide—Somnolence—Methotrexate—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Gadodiamide—Dyspepsia—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Gadodiamide—Fatigue—Methotrexate—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Gadodiamide—Pain—Methotrexate—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Gadodiamide—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000984	0.000984	CcSEcCtD
Gadodiamide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000976	0.000976	CcSEcCtD
Gadodiamide—Urticaria—Methotrexate—lymphatic system cancer	0.000948	0.000948	CcSEcCtD
Gadodiamide—Body temperature increased—Methotrexate—lymphatic system cancer	0.000944	0.000944	CcSEcCtD
Gadodiamide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000944	0.000944	CcSEcCtD
Gadodiamide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00088	0.00088	CcSEcCtD
Gadodiamide—Asthenia—Methotrexate—lymphatic system cancer	0.000857	0.000857	CcSEcCtD
Gadodiamide—Pruritus—Methotrexate—lymphatic system cancer	0.000845	0.000845	CcSEcCtD
Gadodiamide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000817	0.000817	CcSEcCtD
Gadodiamide—Dizziness—Methotrexate—lymphatic system cancer	0.000789	0.000789	CcSEcCtD
Gadodiamide—Vomiting—Methotrexate—lymphatic system cancer	0.000759	0.000759	CcSEcCtD
Gadodiamide—Rash—Methotrexate—lymphatic system cancer	0.000753	0.000753	CcSEcCtD
Gadodiamide—Dermatitis—Methotrexate—lymphatic system cancer	0.000752	0.000752	CcSEcCtD
Gadodiamide—Headache—Methotrexate—lymphatic system cancer	0.000748	0.000748	CcSEcCtD
Gadodiamide—Nausea—Methotrexate—lymphatic system cancer	0.000709	0.000709	CcSEcCtD
